In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 100 of 399

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance	TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]	Technology appraisal guidance	TBC
Bipolar disorder: assessment and management (extraordinary review)	NICE guideline	TBC
Blood transfusion - Tranexamic acid (update)	NICE guideline	26 February 2026
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance	TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Breast cancer guidelines	NICE guideline	TBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448	Technology appraisal guidance	TBC
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]	Technology appraisal guidance	5 November 2025
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	TBC
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Technology appraisal guidance	19 November 2025
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance	TBC
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)	Health technology evaluation	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580	Technology appraisal guidance	30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]	Highly specialised technology	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment	Health technology evaluation	TBC
Colon cancer (adjuvant) - irinotecan [ID379]	Technology appraisal guidance	TBC
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis	Interventional procedures guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	25 February 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]	Technology appraisal guidance	4 March 2026
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [ID6452]	Technology appraisal guidance	5 November 2025
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297	Technology appraisal guidance	TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297	Technology appraisal guidance	28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]	Technology appraisal guidance	TBC
DCVax-L for treating glioblastoma [ID836]	Technology appraisal guidance	TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]	Technology appraisal guidance	TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897	Technology appraisal guidance	TBC
Delgocitinib for treating moderate to severe chronic hand eczema [ID6408]	Technology appraisal guidance	1 October 2025
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]	Technology appraisal guidance	TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]	Technology appraisal guidance	25 March 2026
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance	TBC
Deuruxolitinib for treating severe alopecia areata ID6597	Technology appraisal guidance	TBC
Deutetrabenazine for treating tardive dyskinesia ID6550	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726	Technology appraisal guidance	TBC
Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)	NICE guideline	TBC
Diabetic retinopathy - ruboxistaurin [ID382]	Technology appraisal guidance	TBC

Results per page

10
25
50
All